Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT125 is a novel delta-like ligand 3 (DLL3)-targeting cyclic peptide conjugate developed for integrated theranostic applications, including positron emission tomography (PET) imaging and targeted radionuclide therapy [EP-0040]. Developed by Hangzhou Healthytide Biotechnology and ShanghaiTech University, HT125 is a modified version of the DLL3-targeting monocyclic peptide MC339 [EP-0040]. When conjugated with chelators such as DOTA or NOTA, HT125 can be radiolabeled with diagnostic isotopes (such as fluorine-18 or gallium-68) for PET imaging, or therapeutic isotopes (such as lutetium-177 or actinium-225) for targeted radionuclide therapy [EP-0040]. In preclinical models of DLL3-overexpressing small cell lung cancer (SCLC) and neuroendocrine tumors, radiolabeled HT125 demonstrated high tumor uptake, favorable tumor-to-background contrast, prolonged tumor retention, and significant tumor growth inhibition [EP-0040].
| Indication | Highest phase | Status |
|---|---|---|
| small-cell lung cancer (SCLC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: small-cell lung cancer (SCLC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HT125.
Work on HT125? Claim this page to correct or add information. Claim this page